- ongoing, recruitingPhase III and phase IV (Integrated)
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
This study looks at how well kidney transplant patients respond to COVID-19 and shingles vaccines when their anti-rejection medication is changed. It compares two different drug treatment plans to see which one helps the body make more protective antibodies.
Netherlands - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized crossover clinical trial regarding the blockage of the mineralocorticoid receptor using Eplerenone on the evolution of arterial stiffness in kidney patients one year after transplant: EVATRAN (The effect of Eplerenone on the evolution of Vasculopathy in renal transplant patients).
This study looks at how a drug called eplerenone affects the stiffness of blood vessels in kidney transplant patients. Researchers want to see if it can improve heart and blood vessel health a year after a kidney transplant.
France - ongoing, recruitingTherapeutic use (Phase IV)
CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS
This study is looking at how a common calcium supplement, Calcigran Forte, affects the levels of medicines taken by people who have had a kidney transplant. We want to make sure these important drugs work as well as they should.
Norway - recruitingPHASE2
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
This study looks at a new drug, ALXN2030, to help people who have had a kidney transplant and are now experiencing a problem called antibody-mediated rejection (AMR). We want to see if the drug can help the kidney recover.
United States · Brazil · Canada - authorisedTherapeutic confirmatory (Phase III)
Randomized controlled trial evaluating the impact of mineralocorticoid receptor blockade by eplerenone on echocardiographic abnormalities among kidney graft recipient under calcineurin inhibitors. KT-CANOPY: Cardiac improvement by eplerenone among patients under cyclosporine or tacrolimus for kidney transplantation.
This study looks at how a drug called eplerenone might improve heart health in people who've had a kidney transplant. We want to see if it can help prevent heart problems and if it changes the size and function of the heart.
France